Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vanda Pharmaceuticals
Biotech
Vanda pauses social anxiety program after failing phase 3 trial
A phase 3 trial of Vanda’s social anxiety disorder drug candidate has missed its primary endpoint, prompting the company to put the program on hold.
Nick Paul Taylor
Oct 15, 2026 2:25am
Vanda tackles Wegovy-driven vomiting, sparking race to ph. 3
Nov 18, 2025 10:44am
Vanda sues FDA over months-long hearing delay
Apr 23, 2025 10:33am
Vanda’s CEO pens searing letter to FDA’s Califf after rejection
Jan 9, 2025 10:51am
Vanda receives FDA rejection, issues fiery response
Sep 19, 2024 8:02am
Vanda Pharmaceuticals shares in the red as phase 3 flops
Feb 26, 2020 7:50am
